CMC Biopharmaceuticals and Lundbeck form strategic partnership  

Lundbeck acquires necessary competencies to develop new protein-based drugs

CMC Biopharmaceuticals and Lundbeck have signed a long-term strategic partnership agreement, according to which CMC Biopharmaceuticals is to analyse, develop and manufacture the active ingredients used in new protein-based drugs developed by Lundbeck. The agreement reflects the increasing specialisation that is currently taking place in the pharmaceutical and biotechnological industries as a result of the recently completed mapping of the human genome.



CMC Biopharmaceuticals is expanding its facilities and in August 2003 will move to a new development and production centre in the Copenhagen area. By then, CMC Biopharmaceuticals expects to have a 100 strong workforce, the majority of whom will be senior scientists and technicians with broad pharmaceutical industrial experience. Lundbeck believes that pharmaceutical companies will increasingly adopt similar outsourcing strategies to acquire the necessary expertise that companies such as CMC Biopharmaceuticals can offer. The company considers that the existence of such expertise in Denmark will significantly help place Medicon Valley on the pharmaceutical world map. The news is reported on CMC Biopharmaceuticals' website.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×